Join
Live feed
·
INSIDERFilingvia Quantisnow
Iovance Biotherapeutics Inc. logo

Interim CEO & General Counsel Vogt Frederick G converted options into 15,626 shares and covered exercise/tax liability with 6,638 shares, increasing direct ownership by 2% to 595,447 units (SEC Form 4) to satisfy tax liability

ByQuantisnow·Wall Street's wire, on your screen.
IOVA· Iovance Biotherapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IOVA (Iovance Biotherapeutics Inc.) and more on Quantisnow.